Form 4: Amphastar Pharmaceuticals Director Michael Zasloff Reports Stock and Option Transactions

Director Michael Zasloff reported the acquisition of restricted stock units and stock options in Amphastar Pharmaceuticals.

Summary

• On June 3, 2024, Michael Zasloff, a director of Amphastar Pharmaceuticals, reported acquiring 3,076 restricted stock units (RSUs) and 6,864 stock options.
• The RSUs vest on June 3, 2025.
• The stock options have an exercise price of $42.25 and also vest on June 3, 2025.
• Following these transactions, Zasloff beneficially owns 24,402 shares of common stock and 6,864 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option transactions. The acquisition of shares and options by a director is generally viewed as a mildly positive signal.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.

Key Dates